^
Association details:
| Biomarker: | CHRM3 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Enablex (darifenacin) (Muscarinic receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1090 / 3 - Repurposing an overactive bladder drug to treat chemoresistant lung cancer
Published date:
03/09/2022
Excerpt:
CHRM3 expression was measured in chemonaive NSCLC cells (A549) and chemoresistant cells (A549R), which showed increased expression in A549R cells. Chemoresistant A549R were pretreated with the CHRM3 antagonist darifenacin (Dari, 10 μM, 24 hrs) before treatment with DTX (48 hrs). Crystal violet survival assay and colony formation assays showed a significant reduction in cell survival in the Dari + DTX combination treatment group...
Secondary therapy:
docetaxel